Market Place
Sourcing Support
Kane Biotech Announces $3,000,000 Private Placement Offering
03 Dec 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Third Quarter 2024 Financial Results
28 Nov 2024 //
GLOBENEWSWIRE
Kane Biotech Changes US Partner for Revyve™ Antimicrobial Gel
27 Nov 2024 //
GLOBENEWSWIRE
Kane Biotech to Release Q3 2024 Financial Results on Nov 28, 2024
21 Nov 2024 //
GLOBENEWSWIRE
Kane Biotech Provides Update After FB Dermatology Acquisition
14 Nov 2024 //
GLOBENEWSWIRE
Kane Biotech Gets Health Canada Approval for Revyve™ Gel
14 Nov 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Agreement to Acquire FB Dermatology
12 Nov 2024 //
GLOBENEWSWIRE
Kane Biotech Donates revyve™ Gel to Ukraine
23 Oct 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Exclusive Distribution Agreement With XSONX
17 Oct 2024 //
GLOBENEWSWIRE
Kane Biotech Joins Multinational Corporate Collaboration Project
03 Oct 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Attendance At Wound Care Conferences
26 Sep 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Exercise of Warrants
12 Sep 2024 //
GLOBENEWSWIRE
Kane Biotech Announces DispersinB® Publication and Conference Presentations
29 Aug 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Second Quarter 2024 Financial Results
29 Aug 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Distribution Agreement For revyve™ Wound Gel
28 Aug 2024 //
GLOBENEWSWIRE
Kane Biotech Signs Distribution Agreement For revyve™ Wound Gel
22 Aug 2024 //
GLOBENEWSWIRE
Kane Biotech To Release Q2 2024 Results On August 29
22 Aug 2024 //
GLOBENEWSWIRE
Kane Biotech Gets Funding To Expand Revyve Antimicrobial Wound Gel Line
13 Aug 2024 //
GLOBENEWSWIRE
Kane Biotech`s Revyve™ Wound Gel Gets FDA Approval For Higher Dosage
23 Jul 2024 //
GLOBENEWSWIRE
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
17 Jul 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Issuance of Restricted Share Units
15 Jul 2024 //
GLOBENEWSWIRE
Kane Biotech Signs Global License With Omni Bioceutical Innovations
11 Jul 2024 //
GLOBENEWSWIRE
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel
27 Jun 2024 //
GLOBENEWSWIRE
Kane Biotech Signs Worldwide License Agreement with I-MED Pharma Inc.
25 Jun 2024 //
GLOBENEWSWIRE
Kane Biotech Announces First Quarter 2024 Financial Results
23 May 2024 //
GLOBENEWSWIRE
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
16 May 2024 //
GLOBENEWSWIRE
Kane Biotech Expands Wound Care With Patented Schultz Biofilm Wound Map
15 May 2024 //
GLOBENEWSWIRE
Kane Biotech to Host Investor Webinar
16 Apr 2024 //
GLOBENEWSWIRE
Kane Closes Sale Of STEM Animal Health To Dechra
15 Apr 2024 //
GLOBENEWSWIRE
Kane Biotech Agrees To Sell Stake In STEM Animal Health
11 Apr 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
Kane Biotech Extends Exclusivity Period on its Offer for its in STEM Animal
20 Mar 2024 //
GLOBENEWSWIRE
Kane Biotech to Release4Q FYR 2023 on March 26, 2024 “ Conference Call to Follow
19 Mar 2024 //
GLOBENEWSWIRE
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
08 Mar 2024 //
GLOBENEWSWIRE
Dr. Robert Huizinga Elected to Kane Biotech Board and Appointed Executive Chair
22 Feb 2024 //
GLOBENEWSWIRE
Kane Biotech Files New Patent on revyve„¢ Antimicrobial Wound Gel Spray
31 Jan 2024 //
GLOBENEWSWIRE
Kane Biotech to Present its revyve Antimicrobial Wound Gel
25 Jan 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Special Meeting of Shareholders
18 Jan 2024 //
GLOBENEWSWIRE
Kane Biotech Announces Correction to Press Release
29 Dec 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Amendment to its Credit Facility
28 Dec 2023 //
GLOBENEWSWIRE
Kane Biotech Receives Offer for its Interest in STEM Animal Health
20 Dec 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Improved Third Quarter 2023 Financial Results
28 Nov 2023 //
GLOBENEWSWIRE
Kane Biotech to Release Third Quarter 2023 Financial Results
21 Nov 2023 //
GLOBENEWSWIRE
Kane Biotech Strengthens Board with Biotech Executive
16 Nov 2023 //
GLOBENEWSWIRE
Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve Gel
02 Nov 2023 //
GLOBENEWSWIRE
Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum
25 Oct 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering
12 Sep 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Second Quarter 2023 Financial Results
29 Aug 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Private Placement Offering to its Credit Facility
03 Aug 2023 //
GLOBENEWSWIRE
Kane Engages Research Capital to Conduct Strategic Review of STEM Animal Health
02 Aug 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Issuance of Restricted Share Units
23 Jun 2023 //
GLOBENEWSWIRE
Kane Biotech Announces First Quarter 2023 Financial Results
25 May 2023 //
GLOBENEWSWIRE
Kane Announces FDA 510(k) Clearance for its coactiv+„¢ Antimicrobial Wound Gel
25 May 2023 //
GLOBENEWSWIRE
Kane Biotech to Release First Quarter 2023 Financial Results
18 May 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Distribution Agreement with ProgenaCare Global
20 Apr 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Fourth Quarter and Full Year 2022 Financial Results
20 Apr 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Additional coactiv+â„¢ Animal Health Licensing Agreement
18 Apr 2023 //
GLOBENEWSWIRE
Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results
13 Apr 2023 //
GLOBENEWSWIRE
Kane Biotech Clarifies Terms of Credit Facility
03 Mar 2023 //
GLOBENEWSWIRE
Kane Biotech Announces Amendment to its Credit Facility
02 Mar 2023 //
GLOBENEWSWIRE
